Climb Bio (NASDAQ:CLYM) Coverage Initiated at Robert W. Baird

Key Points

• Robert W. Baird has initiated coverage of Climb Bio (NASDAQ:CLYM) with an "outperform" rating and a price target of $9.00, suggesting a potential upside of 423.26% from its current price.
• Climb Bio's stock has seen a range between a 52-week low of $1.05 and a high of $8.79, with recent trading around $1.72.
• The company recently reported earnings of (-$0.13) per share, exceeding analysts' expectations, as it continues to focus on developing therapies for immune-mediated diseases.

Robert W. Baird began coverage on shares of Climb Bio (NASDAQ:CLYM - Free Report) in a research report sent to investors on Friday, MarketBeat.com reports. The firm issued an outperform rating and a $9.00 price target on the stock.

Other research analysts also recently issued reports about the company. Oppenheimer assumed coverage on Climb Bio in a research note on Friday, June 6th. They set an "outperform" rating and a $10.00 price objective for the company. BTIG Research started coverage on shares of Climb Bio in a research note on Thursday, May 22nd. They set a "buy" rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $9.00.

Climb Bio Stock Performance

CLYM traded up $0.03 on Friday, hitting $2.05. 207,024 shares of the company were exchanged, compared to its average volume of 339,733. The business's fifty day moving average is $1.44 and its 200 day moving average is $1.37. Climb Bio has a fifty-two week low of $1.05 and a fifty-two week high of $8.79. The firm has a market capitalization of $138.92 million, a P/E ratio of -2.93 and a beta of -0.11.

Climb Bio (NASDAQ:CLYM - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06. Analysts forecast that Climb Bio will post -1.57 EPS for the current fiscal year.

Institutional Trading of Climb Bio

A number of institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC bought a new stake in shares of Climb Bio during the 1st quarter worth approximately $27,000. XTX Topco Ltd acquired a new stake in shares of Climb Bio during the first quarter worth $34,000. Qube Research & Technologies Ltd acquired a new position in shares of Climb Bio during the second quarter valued at about $43,000. Marshall Wace LLP bought a new position in Climb Bio during the 2nd quarter valued at $46,000. Finally, Nuveen LLC purchased a new stake in shares of Climb Bio during the 1st quarter valued at $48,000. 69.76% of the stock is owned by institutional investors.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.